Sign In
Buy TNYA
$0.731
+0.0191 (+2.68%)
At Close: Jun 18, 2026
Agreement Combines Tenaya's Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Mill
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
04:05pm, Monday, 02'nd Mar 2026
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti
Insider Selling: Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Sells $2,758,469.64 in Stock
04:54am, Sunday, 15'th Feb 2026
Tenaya Therapeutics, Inc. (NASDAQ: TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 4,056,573 shares of the company's stock in a transaction dated Wednesday, February 11th. The sh
Critical Analysis: Tenaya Therapeutics (NASDAQ:TNYA) vs. Corvus Pharmaceuticals (NASDAQ:CRVS)
02:10am, Monday, 19'th Jan 2026
Corvus Pharmaceuticals (NASDAQ: CRVS - Get Free Report) and Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contr
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
08:30am, Friday, 09'th Jan 2026
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM
Tenaya Stock Plunges After $60 Million Equity Offering
01:56pm, Friday, 12'th Dec 2025
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) stock is trading lower on Friday, with a session volume of 42.39 million compared to the average volume of 3.51 million as per data from Benzinga Pro.
Tenaya Therapeutics Announces Pricing of Public Offering
12:16am, Friday, 12'th Dec 2025
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia
Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript
Tenaya Therapeutics Announces Proposed Public Offering
04:02pm, Thursday, 11'th Dec 2025
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia
MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burd
Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript
03:11pm, Monday, 10'th Nov 2025
Tenaya Therapeutics, Inc. ( TNYA ) Shareholder/Analyst Call November 10, 2025 8:00 AM EST Company Participants Michelle Corral - Vice President of Investor Relationship & Corporate Communications Fara
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
07:00am, Monday, 10'th Nov 2025
Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research
Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™ -1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy
